Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. more
Time Frame | IMRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 4.33% | -1.44% | 0.14% |
1-Month Return | 14.21% | -3.08% | 1% |
3-Month Return | 81.59% | -7.09% | 10.23% |
6-Month Return | 45.64% | -1.54% | 12.9% |
1-Year Return | -69.13% | 8.85% | 30.94% |
3-Year Return | -89.97% | 7.52% | 28.43% |
5-Year Return | -87.66% | 44.8% | 93% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.92M | 2.31M | 2.08M | 316.95K | 455.00 | [{"date":"2019-12-31","value":83.05,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.98,"profit":true},{"date":"2022-12-31","value":13.71,"profit":true},{"date":"2023-12-31","value":0.02,"profit":true}] |
Cost of Revenue | 1.22M | 1.28M | 1.15M | 158.12K | 764.14K | [{"date":"2019-12-31","value":95.52,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":90.06,"profit":true},{"date":"2022-12-31","value":12.35,"profit":true},{"date":"2023-12-31","value":59.68,"profit":true}] |
Gross Profit | 696.74K | 1.03M | 926.89K | 158.83K | (764.14K) | [{"date":"2019-12-31","value":67.57,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.88,"profit":true},{"date":"2022-12-31","value":15.4,"profit":true},{"date":"2023-12-31","value":-74.1,"profit":false}] |
Gross Margin | 36.29% | 44.61% | 44.56% | 50.11% | (167942.42%) | [{"date":"2019-12-31","value":72.43,"profit":true},{"date":"2020-12-31","value":89.02,"profit":true},{"date":"2021-12-31","value":88.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-335136.22,"profit":false}] |
Operating Expenses | 6.99M | 18.11M | 34.81M | 51.90M | 58.41M | [{"date":"2019-12-31","value":11.96,"profit":true},{"date":"2020-12-31","value":31.01,"profit":true},{"date":"2021-12-31","value":59.6,"profit":true},{"date":"2022-12-31","value":88.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (6.29M) | (17.08M) | (33.89M) | (51.74M) | (58.41M) | [{"date":"2019-12-31","value":-629101400,"profit":false},{"date":"2020-12-31","value":-1708255400,"profit":false},{"date":"2021-12-31","value":-3388606900,"profit":false},{"date":"2022-12-31","value":-5174486800,"profit":false},{"date":"2023-12-31","value":-5841288600,"profit":false}] |
Total Non-Operating Income/Expense | (2.84M) | 85.31K | 212.74K | 2.25M | 8.31M | [{"date":"2019-12-31","value":-34.14,"profit":false},{"date":"2020-12-31","value":1.03,"profit":true},{"date":"2021-12-31","value":2.56,"profit":true},{"date":"2022-12-31","value":27.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (7.71M) | (17.04M) | (33.84M) | (50.51M) | (53.47M) | [{"date":"2019-12-31","value":-770944800,"profit":false},{"date":"2020-12-31","value":-1703989800,"profit":false},{"date":"2021-12-31","value":-3384323300,"profit":false},{"date":"2022-12-31","value":-5051356800,"profit":false},{"date":"2023-12-31","value":-5347162200,"profit":false}] |
Income Taxes | 351.30K | (84.34K) | (307.49K) | (1.23M) | 2.00 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-24.01,"profit":false},{"date":"2021-12-31","value":-87.53,"profit":false},{"date":"2022-12-31","value":-350.63,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (8.06M) | (16.96M) | (33.54M) | (49.28M) | (53.47M) | [{"date":"2019-12-31","value":-806075000,"profit":false},{"date":"2020-12-31","value":-1695556200,"profit":false},{"date":"2021-12-31","value":-3353574800,"profit":false},{"date":"2022-12-31","value":-4928179700,"profit":false},{"date":"2023-12-31","value":-5347162400,"profit":false}] |
Income From Continuous Operations | (7.71M) | (17.04M) | (33.54M) | (50.51M) | (51.63M) | [{"date":"2019-12-31","value":-770944800,"profit":false},{"date":"2020-12-31","value":-1703989800,"profit":false},{"date":"2021-12-31","value":-3353574800,"profit":false},{"date":"2022-12-31","value":-5051356800,"profit":false},{"date":"2023-12-31","value":-5163419200,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (8.06M) | (17.04M) | (33.54M) | (49.28M) | (53.47M) | [{"date":"2019-12-31","value":-806075000,"profit":false},{"date":"2020-12-31","value":-1703989800,"profit":false},{"date":"2021-12-31","value":-3353574800,"profit":false},{"date":"2022-12-31","value":-4928179700,"profit":false},{"date":"2023-12-31","value":-5347162200,"profit":false}] |
EPS (Diluted) | (0.65) | (1.26) | (3.76) | (1.92) | (1.89) | [{"date":"2019-12-31","value":-64.66,"profit":false},{"date":"2020-12-31","value":-125.85,"profit":false},{"date":"2021-12-31","value":-376,"profit":false},{"date":"2022-12-31","value":-192,"profit":false},{"date":"2023-12-31","value":-189,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMRX | |
---|---|
Cash Ratio | 7.32 |
Current Ratio | 7.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMRX | |
---|---|
ROA (LTM) | -37.42% |
ROE (LTM) | -61.81% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 563.62 |
P/B | 1.17 |
Price/FCF | NM |
EV/R | 191913.54 |
EV/Ebitda | NM |
Immuneering Corp (IMRX) share price today is $2.17
Yes, Indians can buy shares of Immuneering Corp (IMRX) on Vested. To buy Immuneering Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Immuneering Corp (IMRX) via the Vested app. You can start investing in Immuneering Corp (IMRX) with a minimum investment of $1.
You can invest in shares of Immuneering Corp (IMRX) via Vested in three simple steps:
The 52-week high price of Immuneering Corp (IMRX) is $8.41. The 52-week low price of Immuneering Corp (IMRX) is $1.
The price-to-earnings (P/E) ratio of Immuneering Corp (IMRX) is
The price-to-book (P/B) ratio of Immuneering Corp (IMRX) is 1.17
The dividend yield of Immuneering Corp (IMRX) is 0.00%
The market capitalization of Immuneering Corp (IMRX) is $67.69M
The stock symbol (or ticker) of Immuneering Corp is IMRX